Parkinsons Disease Drugs Market Size, Share and Industry Analysis By Drug Class (Decarboxylase Inhibitors, Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors), Route of Administration (Oral, Injection, Transdermal), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) & Regional Forecast, 2020 - 2029 (Includes COVID-19 Business Impact)

                                          
We have updated Parkinson’s disease drugs Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Parkinson’s disease drugs market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Parkinson’s disease drugs market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Parkinson’s disease drugs Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Parkinson’s disease drugs Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Parkinson’s disease drugs Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

  
Pfizer, Inc.
  
Hoffmann-La Roche Ltd
  
Merck & Co., Inc.
  
Novartis AG
  
Orion Pharma
  
UCB S.A
  
Teva Pharmaceutical Industries Ltd.
  
Vertical Pharmaceuticals, LLC
  
ACADIA Pharmaceuticals Inc.
  
Impax Laboratories, Inc.
  
Lundbeck A/S
  
Other players

Report Overview

Parkinsons disease is a type of neurodegenerative disease that mainly affects the parts of the human brain responsible for controlling movements. Parkinsons disease is caused due to the deterioration of neurons resulting in decreased production of dopamine. Parkinsons disease often results in tremors, stiffness, loss of balance, difficulty in walking, and others. According to the European Parkinsons Disease Association, more than 1.2 million people in Europe are living with Parkinsons Disease, which is expected to double by 2030.

The rising prevalence of the disease has increased the overall healthcare cost in many countries. Parkinsons disease drugs are witnessing increased demands across the globe. Presence of potential pipeline products, increased research and active government support is expected to boost the Parkinsons disease drugs market shares during the forecast period.

The report provides qualitative and quantitative insights on the Parkinsons disease drugs industry and detailed analysis of market size and growth rate for all possible segments in the market. Market is segmented by drug class, route of administration, and distribution channel. Based on drug class, the market is segmented into Decarboxylase Inhibitors, dopamine agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-o-Methyltransferase (COMT) inhibitors and others.

In terms of route of administration, the market is categorized into oral, injection, and transdermal. The distribution channels which are covered under the report are hospital pharmacy, retail pharmacy, and online pharmacy. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.

Along with this, the report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of Parkinsons disease, recent industry developments such as mergers & acquisitions, the regulatory scenario in key countries, new product launch, pipeline analysis, patent analysis, and Parkinsons disease drugs market key industry trends.

SEGMENTATION

By Drug Class

  
 Decarboxylase Inhibitors
  
Dopamine Agonists
  
 Monoamine Oxidase Type B (MAO-B) Inhibitor
  
 Catechol-O-Methyltransferase (COMT) Inhibitors
  
Others

By Route of Administration

  
 Oral
  
Injection
  
 Transdermal

By Distribution Channels

  
Hospital Pharmacy
  
Retail Pharmacy
  
Online Pharmacy

By Geography

  
 North America (USA and Canada)
  
 Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  
 Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  
 Latin America (Brazil, Mexico and Rest of Latin America)
  
 Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Key Industry Developments

In February 2019, Acorda Therapeutics launched INBRIJA, an inhalation powder to treat patient with Parkinsons disease in the U.S.

In October 2018, Pfizer Inc. partnered with Bain Capital to launch a biopharmaceutical company for developing drugs for Parkinsons and other conditions of the central nervous system named Cerevel Therapeutics.

In December 2018, Adamas Pharmaceuticals, Inc. announced the launch of GOCOVRI for the treating dyskinesia in patients having Parkinsons disease.